REPORT: Canadian Society for the Study of the Aging Male: Response to Health Canada's Position Paper on Testosterone Treatment

CSSAM acted as an advocate for hypogonadal men who may benefit from treatment with testosterone. Short-term studies and 60 years of experience with testosterone therapy attest to its efficacy. Long-term studies are desirable, but it may take many years before results could be forthcoming. There is no evidence to suggest that testosterone treatment increases the risk of prostate cancer or cardiovascular disease. Current evidence suggests, in fact, that testosterone treatment may be cardioprotective. It is important to bring this information to the attention of governments and insuring agencies through the collaboration of groups devoted to the diagnosis and treatment of hypogonadal men. Bain J, Brock G, and Kuzmarov I, for the International Consulting Group. Canadian Society for the Study of the Aging Male: Response to Health Canada's position paper on testosterone treatment.